AstraZeneca’s Asthma Treatment Scores European Approval
The European Commission approved AstraZeneca Plc’s (NASDAQ:AZN) Tezspire (tezepelumab) as an add-on maintenance treatment for severe asthma. The approval covers patients…
‘New York City Lifting Covid-19 Vaccine Mandate For Private Sector’ – Abc7NY
https://abc7ny.com/nyc-covid-mask-mandate-new-york-statistics/12242966/?ex_cid=TA_WABC_TW&taid=6329c8841c8e330001002b70&utm_campaign=trueAnthem:+New+Content+(Feed)&utm_medium=trueAnthem&utm_source
AstraZeneca’s COVID-19 Antibody Treatment Scores Approval In Europe
The European Commission has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination as COVID-19 treatment…
AstraZeneca’s COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has backed using AstraZeneca Plc’s (NASDAQ:AZN)…
AstraZeneca Announced Evusheld Long-acting Antibody Combination Recommended for Approval in the EU for the Treatment of COVID-19
AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
AstraZeneca Announced TAGRISSO (osimertinib) Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients with EGFR-mutated Lung Cancer; Data Presented at ESMO 2022
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years